as a result of merger of M/s. Bohara. S.J. & Co, M/s. R.S.Bung & Co and M/s. Pushparaj Bhandari & Co.
The firm was converted into Limited Liability Partnership (LLP) in the month of Oct'2014.
Current strength - 5 Partners, 5 paid qualified assistants, 01 Lawyer and 14 Assistants.
We have a branch at Bengaluru.
We cater to Clients in North Karnataka, Bengaluru, Pune, various other parts of India and abroad.
Established core competencies and knowledge base with dedicated research facilities.
Bohara Bhandari Bung & Associates LLP
2
Our Dedicated Team
CA Bohara Shantilal Jain, Partner - FCA - Experience of around 49 years CA Pushparaj Bhandari, Partner - FCA - Experience of around 38 years CA Rambilas S. Bung, Partner - FCA - Experience of around 37 years CA Pankaj Kumar Bohara, Partner - FCA, DISA - Experience of 18 years
CA Yogesh Bung, Partner - FCA, LLB, Diploma in International Taxation (ICAI) - Experience of over 11 years
Total staff strength of the firm is over 19, of which 5 are qualified Chartered Accountants, 1 is Lawyer, 3 highly experienced staff with over 20 years of experience, 10 Article assistants and Graduate staff.
Bohara Bhandari Bung & Associates LLP
3
Our Aim and Strengths
Our Aim
Our Strengths
"Convert knowledge into value for the benefits of our clients & our people"
"Innovation" is
"Commitment"
the key to
"Quality" in
to our clients
success and we
whatever we do
practice it.
4
Bohara Bhandari Bung & Associates LLP
Our Core Values
We lead by example
We work together as a team We respect the individual We seek facts and provide insight
We believe in openness and honesty in our communication & dealings
Above all, we act with integrity
Bohara Bhandari Bung & Associates LLP
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Shilpa Medicare Ltd. published this content on 24 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 August 2022 10:17:08 UTC.
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in research and development, manufacturing and sale of oncology drugs and formulations. Its products consist of oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. It supplies oncology APIs and intermediates. Its oncology/non-oncology APIs include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib HCL, and Irinotecan HCL Trihydrate for various regulated markets, including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India. It is also engaged in manufacturing and sale of Lenvatinib Capsules under the brand name Lenshil.
SHILPA MEDICARE LIMITED 
